3.3 Respiratory Infections, Exercise & Physiological Stressors

3.3 Respiratory Infections, Exercise & Physiological Stressors

Core Concept: While allergic and chemical exposures stem from foreign environmental matter, asthma exacerbations are frequently provoked by physiological challenges—including viral pathogens, physical exertion, and autonomic neuroendocrine responses. Viral infections represent the single most common cause of life-threatening asthma exacerbations, while exercise-induced bronchoconstriction (EIB) is an exceptionally common manifestation of airway hyperresponsiveness that requires careful pre-exercise management rather than sports avoidance.

Asthmatic airways respond to physiological perturbations with an exaggerated narrowing of the bronchial lumen. In the case of viral infections, intrinsic defects in mucosal antiviral immunity permit rampant viral replication, profound epithelial sloughing, and prolonged exacerbations. In the case of exercise and hyperpnea, massive respiratory heat and water loss provoke osmotic cell shrinkage and vascular engorgement. Understanding these non-allergen physiological triggers enables the Certified Asthma Educator to anticipate high-risk periods, dispel misconceptions about physical activity, and optimize patient self-management plans.

Viral Respiratory Pathogens: The Primary Driver of Asthma Exacerbations

Viral upper and lower respiratory tract infections are implicated in 80% to 85% of pediatric asthma exacerbations and 50% to 70% of adult exacerbations requiring emergency department treatment or hospitalization. While bacterial infections (e.g., Mycoplasma pneumoniae, Chlamydia pneumoniae) can occasionally trigger exacerbations, viruses are overwhelmingly the predominant pathogen.

Key Viral Pathogens

• Human Rhinovirus (HRV): The single most frequent pathogen. HRV is divided into three species: HRV-A, HRV-B, and HRV-C. Discovered in 2006, HRV-C possesses distinct biological tropism for the lower respiratory ciliated epithelium, binds with high affinity to the Cadherin-Related Family Member 3 (CDHR3) receptor, and is associated with exceptionally severe, wheezing exacerbations and intensive care unit admissions in early childhood.
• Respiratory Syncytial Virus (RSV): The preeminent pathogen in infants and children under 2 years of age. Severe RSV bronchiolitis causes bronchiolar epithelial necrosis, peribronchiolar mononuclear infiltration, and uncouples neural M2 inhibitory muscarinic receptors, predisposing infants to recurrent post-bronchiolitic wheeze.
• Influenza Viruses (A and B): Highly cytopathic viruses that cause extensive desquamation of the tracheobronchial ciliated epithelium, exposing underlying sensory nerve endings and triggering explosive inflammatory cytokine storms (IFN-γ, TNF-α, IL-6).
• Other Viral Agents: Parainfluenza, Human Metapneumovirus (hMPV), Adenovirus, and seasonal Coronaviruses.

Epithelial Cellular Receptors and Viral Entry

• ICAM-1 (Intercellular Adhesion Molecule-1 / CD54): Serves as the cellular entry receptor for the major group of HRV (over 90% of HRV-A and HRV-B serotypes). Viral binding upregulates epithelial ICAM-1 expression via NF-κB, creating a positive feedback loop that facilitates widespread infection of adjacent cells.
• CDHR3 (Cadherin-Related Family Member 3): Specifically mediates entry of HRV-C. A specific single nucleotide polymorphism (SNP rs6967330, resulting in a Tyr529Cys substitution) increases cell-surface expression of CDHR3 and confers a dramatic, genetically determined susceptibility to recurrent, life-threatening viral asthma exacerbations in children.

The Innate Interferon Deficiency in Asthmatic Airways

Groundbreaking translational research has revealed that asthmatic airway epithelial cells suffer from an intrinsic innate immune deficiency in their response to respiratory viruses:

1. In healthy individuals, viral double-stranded RNA (dsRNA) activates toll-like receptor 3 (TLR3) and retinoic acid-inducible gene I (RIG-I), prompting rapid, robust synthesis of Type I interferons (IFN-β) and Type III interferons (IFN-λ1, IFN-λ2/3). These interferons induce programmed apoptosis in infected cells, halting viral replication and clearing the virus with minimal tissue destruction.
2. In asthmatic individuals, airway epithelial cells exhibit markedly deficient and delayed induction of IFN-β and IFN-λ. Deficient interferon production permits unrestrained viral replication, prolonged viral shedding, and widespread necrotic cell death.
3. The resultant cytolysis causes extensive epithelial barrier breakdown and triggers massive release of epithelial alarmins (IL-33, IL-25, and TSLP). These alarmins stimulate resident ILC2s and Th2 cells to release massive surges of IL-5 and IL-13, driving acute eosinophilic inflammation, hypersecretion of mucus, and profound airway obstruction.

Pathophysiological Comparison Table

| Trigger / Stressor | Receptor / Physical Driver | Peak Impact Timing | Pathophysiological Cascade | Clinical Manifestations & Management | |---|---|---|---|---|---| | Human Rhinovirus (HRV-A / HRV-C) | ICAM-1 (HRV-A); CDHR3 (HRV-C) on ciliated airway epithelium | Symptoms peak 48–96 hours post-infection; hyperresponsiveness lasts 4–6 weeks | Impaired IFN-β/λ induction → unchecked viral replication → cytolysis → alarmin surge (IL-33/TSLP) → eosinophil and neutrophil influx | Nasal congestion, sore throat followed by severe lower airway wheeze and steroid-resistant airflow obstruction. Annual influenza vaccination; prompt adherence to Yellow Zone action plan (stepping up ICS or ICS-formoterol). | | Respiratory Syncytial Virus (RSV) | CX3CR1, nucleolin, and TLR4 on respiratory epithelial cells | Days 3–5 of illness; prolonged airway instability in infants | Sloughing of necrotic bronchiolar epithelium → intraluminal mucus plugs and cellular debris → loss of inhibitory M2 muscarinic tone | Severe expiratory wheezing, tachypnea, subcostal retractions, feeding difficulty in infants. Monoclonal antibody prophylaxis (nirsevimab) for infants; supportive hydration and oxygenation. | | Exercise: Osmotic Mechanism | Hyperpnea bypassing nasal conditioning → evaporative drying of periciliary liquid | Peaks 5–15 minutes after stopping exertion; resolves within 30–60 minutes | High minute ventilation → dehydration of airway surface liquid → hyperosmolarity → mast cell shrinkage → calcium influx → degranulation of histamine, CysLTs, PGD2 | Post-exertional cough, chest tightness, wheezing, decline in FEV1 ≥10%. Pre-exercise warm-up (induces refractory period); pre-treatment with SABA 5–20 min prior, or low-dose ICS-formoterol. | | Exercise: Thermal / Vascular Mechanism | Intra-airway mucosal cooling during hyperpnea followed by rapid cessation | Peaks 5–15 minutes after exertion upon rapid mucosal rewarming | Hyperventilation cools airway wall → intense vasoconstriction → stopping exercise causes rapid rewarming → reactive microvascular hyperemia and plasma extravasation | Submucosal swelling narrows airway lumen; exacerbated by exercising in cold, dry ambient air. Covering mouth and nose with a scarf/mask during winter sports to pre-warm and humidify inhaled air. | | Autonomic Stress & Emotion | Vagal cholinergic efferents (M3 receptors) and HPA axis glucocorticoid receptor resistance | Acute: within minutes of emotional outburst (laughing, crying); Chronic: sustained over weeks | Extreme emotion causes hyperventilation + vagal parasympathetic discharge (acetylcholine on M3) → bronchospasm; chronic stress elevates cortisol, downregulates beta-2 receptors, upregulates GR-β | Acute wheezing triggered by sobbing, screaming, or hard laughter; chronic anxiety leads to persistent asthma instability and poor symptom perception. Stress-reduction techniques, cognitive behavioral support, anticholinergic adjuncts (ipratropium/tiotropium). |

Exercise-Induced Bronchoconstriction (EIB): The Dual Mechanical Models

Exercise-Induced Bronchoconstriction (EIB) is defined as an acute, transient narrowing of the lower airways that occurs during or, classically, immediately following vigorous physical exertion. Objective diagnosis is confirmed by a fall in FEV1 of ≥10% (and ≥200 mL) from pre-exercise baseline following standardized exercise or surrogate eucapnic voluntary hyperpnea (EVH) challenge.

Vigorous Exercise / High Minute Ventilation (>60–100 L/min) with Oral Breathing
                                     │
             ┌───────────────────────┴───────────────────────┐
             ▼                                               ▼
   Evaporative Water Loss                          Respiratory Heat Loss
(Airway Surface Liquid Dehydration)                (Intra-airway Mucosal Cooling)
             │                                               │
             ▼                                               ▼
Hyperosmolarity of Periciliary Fluid               Deep Mucosal Vasoconstriction
             │                                               │
             ▼                                               ▼
Osmotic Water Extraction from Cells                 Cessation of Physical Exertion
             │                                               │
             ▼                                               ▼
Cellular Shrinkage & Calcium Influx                 Rapid Airway Wall Rewarming
             │                                               │
             ▼                                               ▼
Non-IgE Mast Cell / Basophil Degranulation         Reactive Microvascular Hyperemia
• Histamine, Leukotrienes (LTC4/D4/E4), PGD2       • Engorgement of Venular Plexus
             │                                     • Plasma Extravasation & Edema
             ▼                                               ▼
   Acute Smooth Muscle Spasm                       Physical Wall Thickening
             │                                               │
             └───────────────────────┬───────────────────────┘
                                     ▼
                 Clinical EIB: Airway Luminal Narrowing
                 (Peaks 5–15 min Post-Exercise; Drop in FEV1 ≥10%)

The Osmotic Hypothesis (Airway Dehydration Model)

During strenuous exertion, minute ventilation expands from a baseline of ~6 L/min to over 60–100 L/min. Mouth breathing bypasses the natural air-conditioning capabilities of the nasal turbinates. The cold or dry air travels deep into the bronchial tree, causing rapid evaporation of water from the periciliary fluid layer.

• Hyperosmolar Shock: This evaporative water loss increases the osmolarity of the airway surface liquid (from a normal ~300 mOsm/kg to >350–400 mOsm/kg).
• Cellular Dehydration: Hyperosmolarity draws water out of mucosal epithelial cells and submucosal mast cells via osmosis, causing acute cellular shrinkage.
• Mediator Exocytosis: Cell shrinkage stimulates intracellular calcium mobilization and protein kinase activation, triggering non-IgE-dependent degranulation of mast cells and basophils. This liberates potent spasmogens—histamine, cysteinyl leukotrienes (LTC4, LTD4, LTE4), and prostaglandin D2 (PGD2)—which contract bronchial smooth muscle.

The Thermal Hypothesis (Vascular / Hyperemic Model)

Simultaneously, the continuous passage of unconditioned air removes large amounts of heat from the airway wall, causing local mucosal temperature to drop from 37°C down to 30°C–32°C. In response, bronchial microvascular vessels undergo intense vasoconstriction to preserve core body temperature.

• When the athlete suddenly stops exercising, ventilation abruptly returns to baseline, halting evaporative heat loss.
• The bronchial circulation immediately undergoes rapid, reactive rewarming, resulting in profound reactive hyperemia and engorgement of the submucosal capillary and venular beds.
• The engorged microvasculature leaks fluid into the peribronchial interstitial space, producing acute mucosal edema that mechanically narrows the airway lumen independent of smooth muscle contraction.

The Refractory Period and Warm-Up Protocols

In approximately 50% of individuals with EIB, performing an initial bout of vigorous exercise induces a refractory period lasting 1 to 2 hours. During this refractory window, repeat strenuous exercise provokes substantially less bronchoconstriction or none at all.

• Pathophysiology of Refractoriness: The refractory state is driven by temporary tachyphylaxis (depletion of preformed mediator stores within airway mast cells) combined with the local synthesis and release of protective prostaglandin E2 (PGE2), which inhibits mast cell degranulation and promotes smooth muscle relaxation.
• Clinical Application: Certified Asthma Educators must teach athletes with EIB to harness this phenomenon through a structured interval warm-up protocol. Performing variable-intensity sprints or alternating aerobic intervals (30 seconds of high intensity followed by 2 minutes of low intensity, repeated over 15–20 minutes) prior to athletic competition activates the refractory period, allowing the athlete to perform without post-exertional attacks.
• Pharmacological Protection: Administration of a Short-Acting Beta2-Agonist (SABA, 2 puffs) 5 to 20 minutes before exercise prevents EIB for 2 to 4 hours in over 80% of patients. Alternatively, under NAEPP 2020 and GINA guidelines, as-needed low-dose ICS-formoterol can be used prior to exercise, delivering rapid bronchodilation alongside concomitant anti-inflammatory coverage.